Using the Logistic Regression to Predict Saudi’s Kidney Transplant Rejection Patients

Abstract

Background: Many factors may affect rejection in kidney transplant patients. Tacrolimus is immunosuppressive agent used for the prevention of the rejection in kidney patients which has narrow therapeutic range and variable pharmacokinetics. Many other factors like age, gender, Nephrotoxicity (NT), Fluid Retention (FR) may affect the rejection.

Objectives: To build a predictive model based on the Binary Logistic Regression that can identify the kidne Transplant Rejection Patients that contains only the significant factors only out of all variables measured on Saudi Patients.

Method: The research population consisted of 100 SKTP at the Armed Forces Hospital in the Southern Region (AFHSR) treated with Tacrolimus and followed-up for a period of 24 months (2012 till 2014). Many other variables were measured on these patients.

Results: A significant Binary Logistic model that can be used to detect the factors affect the rejection and the probability of rejection. The significant factors (based on the stepwise logistic regression) where found to be Nephrotoxicity (NT), Fluid Retention (FR) and Tacrolimus trough level (after more than 180 days) (TTL). The Probability of rejection for the kidney can be calculated based on the equation:

\[
\text{Prob (rejection)} = \frac{1}{1 + e^{-z}}
\]

where \(z = 1.004 + 2.769 \times \text{NT} + 24.234 \times \text{FR} - 0.856 \times \text{TTL} \)

Keywords: Logistic regression; Tacrolimus; Kidney transplant; Saudi

Introduction

Organ transplantation requires lifelong pharmacotherapy with combination of immunosuppressant drugs which include a steroid, and immune modulator (e.g. mycophenolate mofetil, and a calcineurin inhibitor [CNI] like cyclosporine A and Tacrolimus [1].

Tacrolimus became an essential component of immunosuppressant regimens in most transplant centers. Its mechanism involve selective suppression of T-lymphocyte and its pharmacokinetic is quite variable among individuals and influenced by so many variables such as race, time after transplantation, and other chronic illness. It is extensively metabolized in the liver by cytochrome P450 3A system (CYP3A), which is subject to considerable inter-individual variation and drug interaction [2]. It produces many adverse reactions which include infections, malignancies, nephrotoxicity, hypertension and diabetes mellitus [3]. Furthermore, Tacrolimus is liable for several drug interactions, primarily with agents affecting the cytochrome P-450 system which include food and herbal medicines. These interactions may lead to serious toxicity or rejection of the transplanted organ [3]. Tacrolimus has narrow therapeutic window; under dosing is associated with an increased risk for rejection, whereas overdosing is associated with higher incidence of dose related toxicity [4].

Marzouk et al. (2017) show that there is a significant relationship between Tacrolimus trough level and incidence of kidney rejection was remarkably found only after 180 days post-transplantation. During this period, Tacrolimus mean trough level (ng/ml) was 7.4 ± 0.2 in SKTP with no rejection, 5.3 ± 0.7 for those with acute rejection, and 3.8 ± 0.4 for those with chronic rejection. Furthermore, the coefficient of variation (CV %) which reflects fluctuation in Tacrolimus trough level, was obviously high in SKTP with acute rejection in all post-kidney-transplant periods.

The aim of present study is to build a predictive model based on the Binary Logistic Regression that can identify the kidney Transplant Rejection Patients that contains only the significant factors measured on Saudi Patients [5,6].

Method

A retrospectively was done during 2012 till 2014, all adult Saudi kidney transplant patients who were followed-up in Kidney Transplant Center in Armed Forces Hospital in the Southern Region are legible for inclusion in the present study.
All adult patients of either sex, in the age group of 18-60 years, recipient of only first renal transplant and those on immunosuppressant therapy comprising of Tacrolimus, MMF and Prednisolone only were included in the study. Patients with more than one kidney transplant procedure, or who use other immune suppression regimen, or Cyclosporine based immunosuppressive therapy. Also patients who show poor drug compliance record or not attend regularly for follow up as scheduled were excluded.

At the AFHSR in Khamis Mushait (Saudi Arabia), the initial Tacrolimus orally dose taken is 0.1 mg/kg/day (two divided doses) and subsequently adjusted as guided by assessment of the patients which includes scheduled Tacrolimus trough level determination (in view of international; guidelines), the following target of Tacrolimus trough level were implemented in SKTP which depend on post transplantation time: 1-14 days (10-12 ng/ml), 15-28 days (8-10 ng/ml), 29 days to 180 days (6-8 ng/ml) and from 180 days onward (5-7 ng/ml). These reference range according to transplant protocol which approved by kidney transplant center in AFHSR.

Parameters used for measurement of outcomes in this study included: acute and chronic rejection kidney rejection as indicated by clinical manifestations (i.e. graft enlargement, fever, malaise, hypertension, oliguria and decreased renal clearance), biopsy test and histopathological findings. Furthermore, post-transplant NODM, hypertension, nephrotoxicity and neurotoxicity were recorded.

The following data were retrieved by the researcher from patients medical record (classic file and computerized system) and recorded in a data collection form which involved for example following items: Demographics: Age, height, weight and BMI. Medical profile: Source of transplanted kidney, Etiology of ESRD, type of induction therapy, current immunosuppressant medication doses, other medications, adverse affects associated with immunosuppressant therapy, incidence of rejection episodes and all relevant lab investigation including Tacrolimus blood trough level (CO), Lab test: chemistry, hematology, serology and immunology test [7].

Statistical analysis

This research uses SPSS 24 software. The findings were processed through descriptive statistics (i.e. mean, SD, and coefficient of variation etc.) and inferential statistics (i.e. testing for significance, using the Chi-square test, t-test, one way Analysis of Variance (ANOVA), correlation and logistic regression). Data are expressed by means ± SE were p value < 0.05 is considered significant.

Results

Demographic characteristics and relevant clinical data are presented in Tables 1 & 2, to allow precise comparison with other similar studies. Out of 100 SKTP enrolled in the present study 59 were males and 41 were females, the mean age ± SD of the patients was 37.4±14.2 years. The median age was 34.5 years, the age ranged between 18 and 60 years, the mean BMI ± SD of the patients was 27.3±6.6 Kg/m². The BMI ranges between 16.4 and 47.4 Kg/m². The median BMI was 26.9 Kg/m².

**Table 1: Demographic data for the sample of SKTP (41 male, 59 female, total 100).**

| Parameter | Relevance | Value |
|-----------|-----------|-------|
| Place of transplantation | AFHSR (Khamis Mushate) | 81 |
| | Other places | 19 |
| Etiology of kidney failure * | Hypertensive nephropathy | 69 |
| | Small kidney + other reasons | 13 |
| | Diabetes mellitus nephropathy | 14 |
| | Unknown | 7 |
| Induction Therapy | Yes | 89 |
| | No reported | 11 |
| HBAg | Reactive | 97 |
| | Non-reactive | 3 |
| HCV | Reactive | 96 |
| | Non-reactive | 4 |
| HIV | Negative | 100 |
| | Positive | 100 |
| CMV-G | Negative | 100 |
| | Positive | 100 |
| CMV-M | Non-relative | 23 |
| | Relative | 59 |
| | Deceased | 18 |

Kidney Transplantation for the majority of the patients (81%) was in AFHSR Khamis Mushait. Records showed that most of the patients (89%) received induction therapy before transplantation. Tacrolimus initial dose was 0.1 mg/kg/day (twice daily). Limited numbers of the patients were reactive for HBAg and HCV (3% and 4% respectively). While all patients were negative for HIV and CMV-M; but they were positive for CMV-G.

Regarding documented etiology of ESRF, hypertension represented the major cause for kidney failure (69%). Followed by diabetes mellitus (14%), Glomerulonephritis among other kidney disorders were also documented as less common reasons for kidney failure.

59% of the patients in the present study received kidney from first grade relative and 23% of them received kidney from living non-relative donors and 18% of the transplanted kidneys were obtained from deceased persons.

Although no significant statistical relationship between the type of donor and incidence of kidney rejection in SKTP (chi-square and Fisher exact tests p-values were > 0.05). The results provided an impression that SKTP received kidney from living related donor showed a relatively lower incidence of rejection episodes compared to those received cadaveric kidney.

Citation: Abdelfattah EH, Al Nasser MS, Ali AS, AbdulSattar MA (2017) Using the Logistic Regression to Predict Saudi's Kidney Transplant Rejection Patients. Biom Biostat Int J 5(2): 00129. DOI: 10.15406/bbij.2017.05.00129
Table 3 summarizes Tacrolimus mean trough level (ng/ml) in different post kidney transplant periods in SKTP classified according to incidence of rejection episodes.

It was noted that the significant relationship between Tacrolimus trough level (ng/ml) and incidence of kidney rejection was only established in the period after 180 days post transplantation. (P-value = 0.001). In this period, Tacrolimus trough level was 7.4 ± 0.2 in patients who showed no rejection; 5.3 ± 0.7 for those who suffered acute rejection episodes and 3.8 ± 0.4 for those subjected to chronic rejection (kidney loss). The CV % which reflects variation between the Tacrolimus level was shown to have its greatest value in SKTP showed acute rejection in all different post kidney transplant periods.

Table 4 shows that 95% confidence interval (CI) Tacrolimus trough level for the patients who showed no rejection episodes: from 1 - 14 days, the range was 11.5 - 12.7 (ng/ml); from 15 - 28 days, it was 9.7 - 10.6 (ng/ml); for the 29th-180 days, it was 8.2 - 9.2 (ng/ml) and for more than 180 days, the proposed range was 6.9 - 7.8 (ng) (Figures 1 & 2).

Logistic Regression

When the dependent variable is binary or has only two values (yes, no), the regression method is known as binary logistic regression. Before this, a method of discriminant analysis was also in practice but this allows direct prediction of group membership but the assumptions of multivariate normality if independent variables is required for prediction rule to be optimal. Logistic regression model requires fewer assumptions than discriminant analysis and even when the assumptions required for discriminant analysis are not met, logistic regression, still performs well. In logistic regression one can directly estimate the probability of an event where as in linear regression it is not possible as they do not fall in the interval 0 to 1.

The method of logistic regression has become the standard method of analysis for the last three decades, when the dependent variable is binary or dichotomous (yes, no). The difference between logistic and linear regression lies both in the choice of a model and assumptions. Once the difference is accounted for, then logistic method of analysis follows the same general principles as used in linear regression. Stepwise regression is a method of fitting regression models in which the choice of predictive variables is carried out by including only significant variables to the model in many steps based on the number of variables to be including to the model. In each step, a variable is considered for addition to or subtraction from the set of explanatory variables.
Using the Logistic Regression to Predict Saudi’s Kidney Transplant Rejection Patients

Figure 1: Correlation between type of donor and incidence of renal rejection in SKTP.

Figure 2: Box plot for median Tacrolimus trough level (ng/ml) in the period 6-24 month after transplantation.
We applied the binary logistic regression by considering having a kidney rejection as a dependent variable and all other variables are considered as independent variables. A significant Binary Logistic model can be used to detect the factors affect the rejection and the probability of rejection. The significant factors (based on the stepwise logistic regression) where found to be Nephrotoxicity (NT), Fluid Retention (FR) and Tacrolimus trough level (after more than 180 days) (TTL). The Probability of rejection for the kidney can be calculated based on the equation [B-28]:

\[ \text{Prob (rejection)} = \frac{1}{1 + e^{-z}} \]

where \( z = 1.004 + 2.769 \times \text{NT} + 24.234 \times \text{FR} - 0.856 \times \text{TTL} \)

The following table summarize the variables coefficients and the corresponding odds ratios (Table 5):

### Interpretation of Odds Ratio

A value of 15.9 of odds ratio for Nephrotoxicity means that with the existence of Nephrotoxicity, there is a chance about 15 times for the kidney rejection in compare of non existence provided all other factors are kept constant.

Also A value of 33.46 E9 of odds ratio for Fluid Retention means that with the existence of Fluid Retention, there is a confirmed kidney rejection in compare of non existence provided all other factors are kept constant.

With the increase of one ng/ml in Tacrolimus trough level (after more than 180 days) the risk of rejection is decreased 0.425 times provided all other factors are kept constant.

As an example on how to use the logistic regression equation for prediction, suppose that a patient has the following measurements: NT= yes, FR= No and TTL=3. Then

\[ z = 1.004 + 2.769 \times 1 + 24.234 \times 0 - 0.856 \times 3 = 1.205 \]

Hence, the probability of rejection:

\[ \text{Prob (rejection)} = \frac{1}{1 + e^{-1.205}} = 0.77 \]

Examples for different possibilities

| Nephrotoxicity | F.R. | Conc. | Probability of Rejection |
|---------------|-----|------|--------------------------|
| Yes           | Yes | 3    | 1                        |
| Yes           | Yes | 8    | 1                        |
| Yes           | No  | 3    | 0.77                     |
| Yes           | No  | 8    | 0.04                     |
| No            | Yes | 3    | 1                        |
| No            | Yes | 8    | 1                        |
| No            | No  | 3    | 0.17                     |
| No            | No  | 8    | 0.00                     |

### Conclusion

Trough level monitoring during the 1st 6 month post transplantation and achievement of target level couldn’t solely exclude the risk of incidence of rejection. After a period of 180 days post-transplantation, inadequate Tacrolimus trough level (<5 ng/ml can lead to chronic rejection (graft loss). Fluctuation in Tacrolimus trough is a major risk factor in incidence of rejection. Monitoring trough level is a valuable tool to adjust the Tacrolimus after 6 month post transplantation and its recommended to keep within 5-8 ug/ml. Further studies are recommended to evaluate the utility of the LSS for TDM of Tacrolimus in SKTP first 6 months post transplantation. The significant factors (based on the stepwise logistic regression) where found to be Nephrotoxicity (NT), Fluid Retention (FR) and Tacrolimus trough level (after more than 180 days) (TTL).

### Acknowledgement

None.

### Conflict of Interest

None.

### References

1. Kremsky AM, Vincenti F, WM B (2011) Immunosuppressants, Tolerogens, and Immuno-stimulants. In: Brunton LL, Juris and Parker KL. Goodman and Gilman’s. The Pharmacological basis of therapeutics. 11: McGraw Hill, New York, USA. p. 1485-1431.
2. Taylor Al, Watson Gj, Bradley JA (2005) Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy. Crit Rev Oncol Hematol 56(1): 23-46.
3. Katabathina V, Menias CO, Pickhardt P, Lubner M, Prasad SR (2015) Complications of Immunosuppressive Therapy in Solid Organ Transplantation. Radiol Clin North Am 54(2): 303-319.
4. Sweetman S (2014) Martindale: the complete drug reference. 40th edn, Pharmaceutical Press, London.
5. De Jonge H, Naens M, Kuypers (2009) New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation. Ther Drug Monit 31(4): 416-435.
6. Mohammad Pour N, Elyasi S, Vahdati N, Mohammadpour AH, Shamsara J (2011) A review on therapeutic drug monitoring of immunosuppressant drugs. Iran J Basic Med Sci 14(6): 485-498.
7. Wallemacq P, Goffinet JS, O’Morchoe S, Rosiere T, Maine GE, et al. (2009) Multi-site analytical evaluation of the Abbott ARCHITECT tacrolimus assay. Ther Drug Monit 31(2): 198-204.
8. Khan S, Hussain T, Azam H, Salhuddin N (2015) Statistical study of risk factors of End Stage Renal Failure in Peshawar, Pakistan. Open Access Maced J Med Sci 3(1): 189-1.
9. El Minshawy OY, Ghabrah T, El Bassuoni E (2014) Diabetic nephropathy as a cause of end-stage renal disease in Tabuk area, Saudi Arabia: a four-year study. Saudi J Kidney Dis Transpl 25(5): 1105-1109.
10. Al-Sayyari AA, Shaheen FA (2011) End stage chronic kidney disease in Saudi Arabia. A rapidly changing scene. Saudi Med J 32(4): 339-346.
11. Hassanien AA, Al-Shaikh F, Vamos EP, Yadegarfar G, Majeed A (2012) Epidemiology of end-stage renal disease in the countries of the Gulf Cooperation Council: a systematic review. JRSM Short Rep 3(6): 38.

12. Al Salehman MH, Kboury HK, Jondeby MS, Burgos NS, Al Hayyan H, et al. (2008) Progression of diabetic nephropathy in Saudi patients with type 2 diabetes mellitus. Endocrinologist 18(5): 230-232.

13. Halimi JM (2013) Low-grade proteinuria and microalbuminuria in renal transplantation. Transplantation 96(2): 121-130.

14. Rodrigo E, Segundo DS, Fernández-Fresnedo G, López-Hoyos M, Benito A, et al. (2015) Within-Patient Variability in Tacrolimus Blood Levels Predicts Kidney Graft Loss and Donor-Specific Antibody Development. Transplantation 100(11): 2479-2485.

15. Shihoira H, Yamada S, Uehara H, Hokama N, Ueda S (2014) Increased plasma tacrolimus concentration after single intravenous administration of voriconazole: a case of drug–drug interaction. Ryukyu Med J 35(1-3): 41-44.

16. Gaynor JJ, Cancio G, Guerra G, Sageshima J, Roth D, et al. (2015) Lower tacrolimus trough levels are associated with subsequently higher acute rejection risk during the first 12 months after kidney transplantation. Transpl Int 29(2): 216-226.

17. Mathew BS, Fleming DH, Jeyaseelan V, Chandy SJ, Annapandian VM, et al. (2008) A limited sampling strategy for tacrolimus in renal transplant patients. Br J Clin Pharmacol 66(4): 467-472.

18. Van Boekel GA, Donders AR, Hoogtanders KE, Havenith TR, Hilbrands LB, et al. (2015) Limited sampling strategy for prolonged-release tacrolimus in renal transplant patients by use of the dried blood spot technique. Eur J Clin Pharmacol 71(7): 811-816.

19. Jusko WJ, Thomson AW, Fung J, McMaster P, Wong SH, et al. (1995) Consensus document: therapeutic monitoring of tacrolimus (FK-506). Ther Drug Monit 17(6): 606-614.

20. Gaston RS (2001) Maintenance immunosuppression in the renal transplant recipient: an overview. Am J Kidney Dis 36(6): S25-S35.

21. Hardinger K, Brennan DC (2016) Maintenance immunosuppressive therapy in renal transplantation in adults.

22. Lam S, Partovi N, Ting LS, Ensom MH (2008) Corticosteroid interactions with cyclosporine, tacrolimus, mycophenolate, and sirolimus: fact or fiction? Ann Pharmacother 42(7): 1037-1047.

23. Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, et al. (1995) Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 29(6): 404-430.

24. Cheng Y, Li H, Meng Y, Liu H, Yang L, Xu T, et al. (2015) Effect of CYP3A5 polymorphism on the pharmacokinetics of tacrolimus and acute rejection in renal transplant recipients: experience at a single centre. International Journal of Clinical Practice 69(S183): 16-22.

25. Yang TH, Chen YK, Xue F, Han LZ, Shen CH, et al. (2015) Influence of CYP3A5 genotypes on tacrolimus dose requirement: age and its pharmacological interaction with ABCB1 genetics in the Chinese paediatric liver transplantation. Int J Clin Pract Suppl (S183): 53-62.

26. Fathy M, Kamal M, Mohy M, Nabil A (2016) Impact of CYP3A5 and MDR-1 gene polymorphisms on the dose and level of tacrolimus among living-donor liver transplanted patients: single center experience. Biomarkers 21(4): 335-341.

27. Rančić N, Dragojević-Simić V, Vavić N, Kovačević A, Šegrt Z, et al. (2015) Tacrolimus concentration/dose ratio as a therapeutic drug monitoring strategy: the influence of gender and comedication. Vojnosanit Preg 72(9): 813-822.

28. Al-Nasser MS, Ali AS, Abdul Sattar MA, Abdelfattah EH, Khan LM, et al. (2016) Therapeutic Drug Monitoring of Tacrolimus in Saudi Kidney Transplant Patients. J Nephrol Ther 1: 5.